Skip to Content

Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

In this MEDtalk, the ADAURA study is presented by Masahiro Tsuboi, a Thoracic surgeon in Japan. The study explores osimertinib as adjuvant therapy for patients with resected EGFR-mutated non-small-cell lung cancer and indicates osimertinib to be an effective adjuvant treatment for these patients.

Masahiro Tsuboi

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top